SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Pictured: Skyline of Atlanta
Manufacturing
UCB Investing $2B To Build Manufacturing Facility in Georgia
The Belgian drugmaker plans to hire about 330 people at a facility that will use advanced manufacturing technologies including AI, robotics and automation to meet rising demand for key products. This will be UCB’s first biologics manufacturing facility in the U.S.
March 25, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Microscopes, books and test tubes amidst colorful balls on a pink background.-3d rendering."n
FDA
FDA Blueprint Aims To Cut Regulatory Risk for Alternatives to Animal Testing
Draft guidance, issued by the FDA last week, could remove ambiguity and uncertainty that may have so far limited uptake of new approach methodologies, experts told BioSpace, particularly emphasizing the agency’s recommendations around defining NAMs’ regulatory purpose.
March 24, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Symbolic image: Tablets, US Dollar and China - Dependence on the Chinese pharmaceutical industry
Manufacturing
Novartis Pledges $480M To Expand China Presence, Following Eli Lilly and AstraZeneca
Like its pharma peers, Novartis is pouring money into Chinese operations, including expansions and upgrades at an existing manufacturing facility.
March 24, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Illustration of a business person giving a presentation in front of a board of directors, vector illustration
Business
Tang Seizes Control of Aurinia, Taking CEO Post in Total Transformation of C-Suite
Healthcare investor Kevin Tang and his allies now hold almost every leadership position at Aurinia Pharmaceuticals, the company at the heart of former CDER Director George Tidmarsh’s exit from the FDA.
March 23, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Upward arrow on the background of the flag of China. Paper plane. Economic recovery. Copy space. Business. Background.
Manufacturing
AstraZeneca Building Shanghai Production Plant to Support Cell Therapy Strategy
The company is establishing commercial production capabilities to fuel plans to launch autologous CAR T cell therapies in China.
March 19, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Photo of Philadelphia downtown city skyline
Manufacturing
TerraPower Commits $450M To Build Radioisotope Production Plant
Constructing the cGMP facility will increase availability of actinium-225, a nuclear material central to radiopharmaceutical programs at AstraZeneca, Bristol Myers Squibb, Eli Lilly and Novartis.
March 18, 2026
 · 
2 min read
 · 
Nick Paul Taylor
FDA signage at its headquarters in Maryland
Manufacturing
FDA Sets Scope for Attempt To Reduce Manufacturing-Related Approval Rejections
Industry and FDA representatives have reached a general agreement on planned pre-submission facility meetings but have expressed different views about the specifics.
March 10, 2026
 · 
2 min read
 · 
Nick Paul Taylor
change business management, businessman turn gear cog to manage change direction arrows, professional or expertise to manage company transformation or implement new process concept vector illustration
Manufacturing
Cell and Gene Therapy Manufacturing Market To Skyrocket to $146B by 2032
Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production.
March 10, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Concept 3d illustration of a collocated containers as though a computer game due to imports tariffs.
Manufacturing
Nonprofit Aims To Modernize Manufacturing by Clearing Capital Hurdle
Industry groups have identified upfront costs as a barrier to streamlining U.S. drugmaking. The nonprofit API Innovation Center has a proposed answer for how to tilt finances in favor of investments in continuous manufacturing.
March 10, 2026
 · 
5 min read
 · 
Nick Paul Taylor
Cooperation concept. Vector of a businessman and a businesswoman connecting the bridge with a missing part
GLP-1s
Novo Nordisk Agrees To Sell GLP-1 Drugs Via Hims & Hers, Ending Dispute
The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that could increase access to Novo’s obesity medicines.
March 9, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Illustration of a yellow envelope on a blue background with a read warning symbol
Supply chain
FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP-1s
Having targeted Hims & Hers last year, the FDA has issued warnings to more telehealth companies over their promotion of GLP-1 drugs used to treat diabetes and obesity. In one case, compounded products were linked with multiple ER visits.
March 4, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Downtown Holly Springs , North Carolina,
Manufacturing
How North Carolina Attracted Amgen and Roche To Become a Next-Gen Obesity Drug Production Hotspot
Infrastructure and location have helped make Holly Springs a future hub for obesity drug production, with Amgen and Roche planning to manufacture GLP-1 therapies there to compete in the growing market.
March 3, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Medicine Pill Treatment Seamless Vector Flat Pattern
Manufacturing
Novo Commits $506M To Repurpose Irish Plant for Oral Wegovy Production
As Novo Nordisk continues to lose ground in the obesity market to rival Eli Lilly, the Danish company has started construction projects to establish the ex-Alkermes plant as a hub for supplying oral GLP-1 products to global markets.
March 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Creative pattern made with a syringe on pastel pink background. Vaccine for Coronavirus infection. Pandemic concept.
Vaccines
Uncertainty Looms Over Pharma’s Legal Strategy as States Challenge New Vaccine Schedule
The CDC’s changes threaten to cut vaccine sales for makers including Pfizer, Moderna, Merck and more, but a legal expert suspects affected manufacturers will stay on the sidelines rather than back a push to declare the revised schedule unlawful.
February 27, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Aerial photo hotels in Denton, Texas
Manufacturing
Novartis Names Texas City as Location of Its 5th US Radiopharmaceutical Facility
The Denton site is part of a network of manufacturing plants Novartis is building across the U.S. to make cancer drugs that must be shipped to patients quickly.
February 25, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Load More